EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multi-Center Trial.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs EP 100 (Primary) ; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Esperance Pharmaceuticals

23 Nov 2020 Results published in the Gynecologic Oncology
02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
01 Jun 2015 According to an Esperance Pharmaceuticals media release, data from this trial were presented at the American Society of Clinical Oncology (ASCO) Annual meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com